Crescent Biopharma, Inc. (CBIO)vsRevolution Medicines Inc (RVMD)
CBIO
Crescent Biopharma, Inc.
$18.00
-2.44%
HEALTHCARE · Cap: $495.80M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Crescent Biopharma, Inc. generates 1501% more annual revenue ($11.88M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CBIO earns a higher WallStSmart Score of 25/100 (F).
CBIO
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CBIO
The strongest argument for CBIO centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CBIO
The primary concerns for CBIO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CBIO is growing revenue faster at 0.0% — sustainability is the question.
CBIO generates stronger free cash flow (-9M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CBIO scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Crescent Biopharma, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?